MetaCap

Guardant Health Inc. (GH)

NASDAQ: GHHealth CareMedical SpecialitiesUSD

145.83+0.24 (+0.16%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

GH stock chart

Technical analysis

Key statistics

All statistics
Market cap
$19.73B
EPS (TTM)
-$3.68
52-week range
74.55 – 191.05
Day range
141.01 – 148.26
Volume / Avg
2.76M / 1.97M
Beta
—

52-week range

$74.55$191.05

GH stock today

Shares of Guardant Health (GH) finished higher on Nov 20 at $145.83, a gain of 0.16% or $0.24 per share, versus the S&P 500's 3.70% decline. Shares are 23.7% below their 52-week high of $191.05, set on Oct 6, 2026 and 95.6% above the 52-week low of $74.55, in the middle of the past year's range. GH is up 42.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 38.3%.

Guardant Health has posted a net loss over the last twelve months (EPS of -$3.68), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Guardant Health

Company profile

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults.

Industry
Medical Specialities
CEO
Dr. Helmy Eltoukhy Ph.D.
Headquarters
Palo Alto, CA
Employees
2,490
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Guardant Health generated $982.0 million in revenue, up 32.9% from fiscal 2024, its 8th consecutive year of revenue growth. Guardant Health reported a net loss of $416.3 million, compared with a loss of $436.4 million a year earlier. Gross margin was 64.5% (up from 60.8%) and operating margin -44.5%.

Guardant Health annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$982.02M$739.02M$563.95M$449.54M$373.65M
Growth+32.88%+31.04%+25.45%+20.31%+30.32%
Net income$-416.28M$-436.37M$-479.45M$-654.59M$-384.77M
EPS (diluted)$-3.32$-3.56$-4.28$-6.41$-4.00

Analyst forecast

Forecast

Consensus (26 analysts)

strong_buy

Avg. price target

$200.76+37.67%

  • Strong buy 4
  • Buy 21
  • Hold 0
  • Sell 0
  • Strong sell 1

Target range

Low $105.00High $240.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.74 vs $-0.68
Surprise
-8.82%

GH news

All GH news

Guardant Health peers

Health Care sector
GH peer companies
CompanyPrice% ChgMarket capCompare
DGXQuest Diagnostics Incorporated258.28-0.31%$28.42Bvs GH
MOHMolina Healthcare Inc198.39-2.43%$10.36Bvs GH
ILMNIllumina Inc.192.82-3.90%$29.15Bvs GH
LHLabcorp Holdings Inc.367.13-0.47%$29.81Bvs GH
HSICHenry Schein Inc.83.52-1.51%$9.23Bvs GH
CNCCentene Corporation63.78-2.74%$31.58Bvs GH
OSCROscar Health Inc. Class A24.73-5.50%$7.68Bvs GH
RDNTRadNet Inc.69.71+0.29%$5.49Bvs GH

Indexes, lists and sector

Guardant Health stock FAQ

What is Guardant Health's stock price today?

GH last traded at $145.83 as of Nov 20, 4:00 PM EST, up 0.16% on the day. Prices are delayed at least 15 minutes.

Who is Guardant Health's CEO?

Dr. Helmy Eltoukhy Ph.D. is the chief executive officer of Guardant Health Inc., which has about 2,490 employees.

What is the GH 52-week high?

The 52-week high for GH is $191.05 and the 52-week low is $74.55. The stock is currently 23.7% below its high.

Compare GH